Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OFIX
SellSinkerOrthofix Medical Inc. · Healthcare · United States · $392M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Orthofix Medical Inc. is a global medical device company focused on musculoskeletal products and therapies, including spine fixation, biologics, bone growth therapies, and extremity fixation. The company differentiates itself through a portfolio of clinically proven products and proprietary technologies, particularly in bone growth stimulation and advanced spinal solutions. Orthofix is a specialized medical device company committed to advancing musculoskeletal health through innovative bone and spine solutions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 460.7M | 746.6M | 799.5M | 822.3M | 21.3% | 833.2M | 850.9M | 871.9M | 3.0% |
| EPS | -0.49 | -4.12 | -3.30 | -2.33 | — | -1.52 | — | — | — |
| Shares | 40.4M | 37.2M | 38.5M | 39.8M | -1.5% | 40.4M | — | — | — |
| Debt | 21.5M | 117.1M | 179.6M | 178.4M | 102.4% | 261.9M | — | — | — |
| Equity | 336.9M | 598.7M | 503.1M | 450.0M | 10.1% | — | — | — | — |
| Op CF | -11.5M | -45.8M | 25.8M | 33.3M | 29.3% | 16.3M | — | — | — |
| Inv CF | -24.5M | -33.1M | -27.6M | -34.6M | — | — | — | — | — |
| Fin CF | -78.0K | 65.3M | 50.7M | -0.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OFIX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OFIX | Orthofix Medical Inc.(you) | $392M | 27 | Sell |
| SENS | Senseonics Holdings, Inc. | $493M | 29 | Sell |
| NPCE | NeuroPace, Inc. | $495M | 32 | Sell |
| MOBI | Mobia Medical, Inc. | $378M | 15 | Strong Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 16 | Strong Sell |
| RXST | RxSight, Inc. | $293M | 19 | Strong Sell |
| CTKB | Cytek Biosciences, Inc. | $608M | 32 | Sell |
| CERS | Cerus Corporation | $534M | 37 | Hold |
| CATX | Perspective Therapeutics, Inc. | $355M | 12 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%